Israel’s Teva has reported positive results from Phase III trials of its chronic migraine treatment fremanezumab.  Patients experienced statistically significant reduction in the number of moderate severity headache days vs the placebo. FDA approval is expected by end 2017.

http://www.globes.co.il/en/article-teva-reports-positive-phase-iii-migraine-drug-trial-results-1001190672